Fig. 1.

Pooled shRNA screen identifies BCL2L1 as a sensitizing gene for splicing modulator E7107. a Schematic representation of the pooled shRNA screening in NALM6 cells treated with solvent DMSO or E7107. b Volcano plot demonstrating the log₂(fold change) and adjusted p value (moderated t test by limma) of each shRNA in the pool screen (E7107 vs. DMSO, biological duplicates). For log₂(fold change), negative and positive numbers represent drop-out (sensitization) and enrichment (resistance) phenotype, respectively, in combination with E7107 treatment. Red dots show shRNAs that are significantly (adjusted p < 0.05) altered in the screen. c Waterfall plot showing the average log₂(fold change) (E7107 vs. DMSO) of shRNAs targeting the same gene included in the shRNA pool. Five antiapoptotic and two proapoptotic BCL2 family genes were marked in black. d Schematic representation of a GFP-tracking phenotypic validation using single shRNAs against BCL2L1 in NALM6 cells. e FACS analysis of the percentage of GFP-positive NALM6 cells infected by individual shRNAs after 72 h treatment with DMSO or E7107. Data represent means ± SD of biological duplicates. *p < 0.05, n.s. not significant, p > 0.05 by Student’s t test